Improvements have been made in the management of ischemic stroke, including the use of a fibrinolytic agent
known as tissue plasminogen activator (tPA), and the utilization of stroke response teams.
When compared with older fibrinolytic agents
, RETAVASE distinguishes itself by its ease of administration - a simple two-bolus injection given 30 minutes apart.
Patient demographic and clinical characteristics included sociodemographic variables (gender, age); medical history (hypertension, diabetes, dyslipidemia); the admission time of day (day, evening, or night); and admission day of week (weekday or weekend), the presence of chest pain, the location of myocardial infarction, the fibrinolytic agent
used, the percentages of post-fibrinolytic TIMI-3 flow, and post-fibrinolytic CABG.
These results were supported by the CLARITY study of almost 3,500 patients, who were within 12 hours of the onset of a STEMI and were slated to undergo thrombolysis; they received clopidogrel or placebo (they also were treated with aspirin, a fibrinolytic agent
, and when indicated, 48 hours of heparin).
for the commercial manufacture of Retavase[R] (reteplase), a fibrinolytic agent
that has been marketed in North America since October 1996.
Retavase is a fibrinolytic agent
used to treat patients who suffer from heart attacks.
Retavase, a fibrinolytic agent
, has been approved for marketing by the regulatory authorities in Canada and will soon be available to hospitals nationwide.
Recently, research has focused on the possibility of reopening the blood vessel immediately with GP IIb-IIIa inhibitor therapy alone or in combination with a reduced-dose fibrinolytic agent
, followed by PCI to repair the source of blood vessel blockage.
RETAVASE, a fibrinolytic agent
that is administered in two fixed doses and does not require a patient to be weighed before it is administered, facilitates treatment in the pre-hospital setting," said Donald Rosenberg, M.
The company's pipeline of research projects also includes a liposomal fibrinolytic agent
which it has recently licensed.
1% of patients (2 of 28) received fibrinolytic agents
before percutaneous coronary intervention; the remainder underwent primary percutaneous coronary intervention.
You will see commercial prospects for platelet aggregation inhibitors, anticoagulant treatments, fibrinolytic agents
and their subgroups to 2021.